The product helps in the overall show of Rs 93 cr 9% in Q3 net profit

New Delhi: the main products of biotechnology today Rs crore net profit in areas at 9.38 percent increase posted in the third quarter, the overall growth in the different business areas for back on 31 December 2012.

Based in Bangalore, the company's net income for the same period of the previous year has posted Rs crore 84.85.

The company's net sales in the same period of fiscal year 2011-12 Rs Rs crore for the third quarter as opposed to 516.59 634.22 million were recorded.

Kiran Mazumdar Shaw, head of the product. Reuters

Extending a volume, price increases and improved export realisations re-growth product, Chairman and Managing Director, said the company's earnings results show Mazumdar-key for comments.

"We have performed well throughout all our business areas. We are now an important part of our business that occupies the rest of the world (row) market for Biosimilar insulin to gain market share, "Shaw added.

During the quarter, the company relocated, such as accounting 22 percent business growth biopharma period, improved product mix again, he said.

"Sales of $ 50,000 to record through our joint venture to gain critical mass in the Middle East is our official NeoBiocon starting a business" products, said in a statement.

9 months ended 31 December 2012, the company's sales for the Rs 1 crore to Rs while at 797.48 261.74, billion, posted a net profit.

The company is a global phase III biosimilar trastuzumab (for certain types of breast cancer treatment) the successful completion of clinical research for the global stage for the post has started to register patients.

The ongoing phase III trial is being conducted in India continue to add good progress.

The company is the second part of the biosimilar insulin, the 12-month rate of rh-period comparison of immunogenicity and safety innovations for the purposes established in the European Union, said the conclusion of the trial phase III.

"This is the first part of the study the efficacy data obtained from the data are compiled with."Therefore, marketing approval, paving the way for regulatory authorities and submit our dossier then it is added.

Previous close 0.72 percent in afternoon trade on the BSE at Rs 265.55 products stock trading.

During the quarter, the company Bristol Myers Squibb (BMS) and of the global clinical development program in 106 oral insulin contracted for.

"The United States is a strategic alliance partnership with BMS IND (investigational new drug) to the target global helps to conduct experiments. The completion of these trials an exclusive worldwide license, BMS post exercise options for, "the company said.

Future prospects the company total revenue biosimilars, research services and aims to contribute to the official brand was high.

"Our discussions with potential partners in the global marketplace, our new portfolio of insulin and for giving," it added.

A separate statement from the company, has been appointed Board of United States Pharmacopeial Convention show (USP) is a scientific non-profit organisation said.

USP identity, strength, quality and purity, and to develop standards for drugs and drug ingredients, medicinal plant ingredients, dietary supplements, food and drug manufacturing, preparation, distribution and worldwide consumption mix.

"She should be the policy, finance and strategic direction on a map of USP to USP Biologics will serve as a member of the consultative group," the company said.

Union